Health-Chem Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCLC research report →
About the company
Health-Chem Corporation, operating through its subsidiary, Transderm Laboratories Corporation, specializes in the research, development, manufacturing, and commercialization of transdermal drug delivery systems throughout the United States. Among its key products are transdermal nitroglycerin patches, formulated to provide relief for vascular and cardiovascular symptoms linked to angina pectoris (commonly known as chest pain) via skin absorption. The company additionally offers contract research and development services to third-party clients.
- CEO
- Ronald J. Burghauser
- IPO
- 1972
- Employees
- 55
- HQ
- Emigsville, PA, US
Price Chart
- Market Cap
- $73.98K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -12.55
- Div Yield
- 0.00%
- Gross Margin
- 9.81%
- Op Margin
- 44.51%
- Net Margin
- -27.88%
- ROE
- 10.51%
- ROIC
- -31.87%
- Revenue
- $5.94M · -21.70%
- Net Income
- $-1,656,000 · 33.23%
- EPS
- $-0.14 · 36.36%
- Op Income
- $2.64M
- FCF YoY
- 216.33%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -26.02
- Avg Volume
- 0
Get TickerSpark's AI analysis on HCLC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HCLC coverage
Recent articles, reports, and earnings notes.
No research on HCLC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HCLC report →Similar companies
Peers in the same neighborhood.